SMT202100216T1 - Regimi di trattamento di amisulpride per trattare nausea e vomito - Google Patents
Regimi di trattamento di amisulpride per trattare nausea e vomitoInfo
- Publication number
- SMT202100216T1 SMT202100216T1 SM20210216T SMT202100216T SMT202100216T1 SM T202100216 T1 SMT202100216 T1 SM T202100216T1 SM 20210216 T SM20210216 T SM 20210216T SM T202100216 T SMT202100216 T SM T202100216T SM T202100216 T1 SMT202100216 T1 SM T202100216T1
- Authority
- SM
- San Marino
- Prior art keywords
- amisulpride
- vomiting
- dosage regimens
- treating nausea
- nausea
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506116.1A GB201506116D0 (en) | 2015-04-10 | 2015-04-10 | Kit and combination therapy for nausea and vomiting |
| PCT/GB2016/050998 WO2016162695A1 (en) | 2015-04-10 | 2016-04-11 | Combinations of amisulpride and another anti-emetic for treating nausea and vomiting |
| EP16716659.4A EP3280392B1 (en) | 2015-04-10 | 2016-04-11 | Dosage regimens of amisulpride for treating nausea and vomiting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202100216T1 true SMT202100216T1 (it) | 2021-05-07 |
Family
ID=53333601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20210216T SMT202100216T1 (it) | 2015-04-10 | 2016-04-11 | Regimi di trattamento di amisulpride per trattare nausea e vomito |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10322106B2 (enExample) |
| EP (1) | EP3280392B1 (enExample) |
| JP (1) | JP6812360B2 (enExample) |
| KR (2) | KR20240125705A (enExample) |
| CN (1) | CN107872975A (enExample) |
| AU (1) | AU2016246104B2 (enExample) |
| CA (1) | CA2982251C (enExample) |
| CY (1) | CY1124184T1 (enExample) |
| DK (1) | DK3280392T3 (enExample) |
| ES (1) | ES2866933T3 (enExample) |
| GB (1) | GB201506116D0 (enExample) |
| HR (1) | HRP20210624T1 (enExample) |
| HU (1) | HUE054165T2 (enExample) |
| IL (2) | IL295650A (enExample) |
| LT (1) | LT3280392T (enExample) |
| MX (1) | MX388735B (enExample) |
| PL (1) | PL3280392T3 (enExample) |
| PT (1) | PT3280392T (enExample) |
| RS (1) | RS61760B1 (enExample) |
| SI (1) | SI3280392T1 (enExample) |
| SM (1) | SMT202100216T1 (enExample) |
| WO (1) | WO2016162695A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) * | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| AU2018379992B2 (en) | 2017-12-05 | 2022-07-21 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| US10377708B2 (en) | 2017-12-05 | 2019-08-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| US11160758B2 (en) | 2019-06-04 | 2021-11-02 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| EP4496797A1 (en) | 2022-03-21 | 2025-01-29 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| JP2025513071A (ja) | 2022-04-14 | 2025-04-22 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| EP4634180A1 (en) | 2022-12-15 | 2025-10-22 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| EP4638440A1 (en) | 2022-12-22 | 2025-10-29 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024138048A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| IL322686A (en) | 2023-02-16 | 2025-10-01 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
| TW202506102A (zh) | 2023-06-30 | 2025-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環的glp-1促效劑 |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| AR133240A1 (es) | 2023-07-13 | 2025-09-10 | Aconcagua Bio Inc | Compuestos, composiciones y métodos |
| WO2025045208A1 (en) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201003962D0 (en) | 2010-03-10 | 2010-04-21 | Tangentix Ltd | Multimedia content delivery system |
| GB201004020D0 (en) * | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| CN103906514A (zh) * | 2011-09-13 | 2014-07-02 | 拜奥迈德瓦利探索有限公司 | 用于治疗代谢障碍的组合物和方法 |
-
2015
- 2015-04-10 GB GBGB1506116.1A patent/GB201506116D0/en not_active Ceased
-
2016
- 2016-04-11 CN CN201680030994.9A patent/CN107872975A/zh active Pending
- 2016-04-11 KR KR1020247026775A patent/KR20240125705A/ko active Pending
- 2016-04-11 RS RS20210407A patent/RS61760B1/sr unknown
- 2016-04-11 WO PCT/GB2016/050998 patent/WO2016162695A1/en not_active Ceased
- 2016-04-11 EP EP16716659.4A patent/EP3280392B1/en active Active
- 2016-04-11 SM SM20210216T patent/SMT202100216T1/it unknown
- 2016-04-11 ES ES16716659T patent/ES2866933T3/es active Active
- 2016-04-11 HR HRP20210624TT patent/HRP20210624T1/hr unknown
- 2016-04-11 HU HUE16716659A patent/HUE054165T2/hu unknown
- 2016-04-11 MX MX2017012991A patent/MX388735B/es unknown
- 2016-04-11 PT PT167166594T patent/PT3280392T/pt unknown
- 2016-04-11 LT LTEP16716659.4T patent/LT3280392T/lt unknown
- 2016-04-11 JP JP2017553076A patent/JP6812360B2/ja active Active
- 2016-04-11 IL IL295650A patent/IL295650A/en unknown
- 2016-04-11 AU AU2016246104A patent/AU2016246104B2/en active Active
- 2016-04-11 SI SI201631183T patent/SI3280392T1/sl unknown
- 2016-04-11 CA CA2982251A patent/CA2982251C/en active Active
- 2016-04-11 DK DK16716659.4T patent/DK3280392T3/da active
- 2016-04-11 US US15/565,479 patent/US10322106B2/en active Active
- 2016-04-11 PL PL16716659T patent/PL3280392T3/pl unknown
- 2016-04-11 KR KR1020177032393A patent/KR102711661B1/ko active Active
-
2017
- 2017-10-08 IL IL254929A patent/IL254929A0/en unknown
-
2021
- 2021-05-20 CY CY20211100442T patent/CY1124184T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL254929A0 (en) | 2017-12-31 |
| MX2017012991A (es) | 2018-02-01 |
| JP6812360B2 (ja) | 2021-01-13 |
| AU2016246104B2 (en) | 2018-12-13 |
| EP3280392A1 (en) | 2018-02-14 |
| SI3280392T1 (sl) | 2021-08-31 |
| PL3280392T3 (pl) | 2021-10-18 |
| KR20240125705A (ko) | 2024-08-19 |
| IL295650A (en) | 2022-10-01 |
| CA2982251C (en) | 2023-06-13 |
| KR102711661B1 (ko) | 2024-10-02 |
| JP2018510898A (ja) | 2018-04-19 |
| EP3280392B1 (en) | 2021-02-24 |
| KR20180016350A (ko) | 2018-02-14 |
| US20180071249A1 (en) | 2018-03-15 |
| PT3280392T (pt) | 2021-03-12 |
| AU2016246104A1 (en) | 2017-11-30 |
| WO2016162695A1 (en) | 2016-10-13 |
| GB201506116D0 (en) | 2015-05-27 |
| CY1124184T1 (el) | 2022-07-22 |
| CA2982251A1 (en) | 2016-10-13 |
| HRP20210624T1 (hr) | 2021-05-28 |
| LT3280392T (lt) | 2021-04-26 |
| ES2866933T3 (es) | 2021-10-20 |
| DK3280392T3 (da) | 2021-03-08 |
| MX388735B (es) | 2025-03-20 |
| US10322106B2 (en) | 2019-06-18 |
| HK1250913A1 (en) | 2019-01-18 |
| RS61760B1 (sr) | 2021-05-31 |
| HUE054165T2 (hu) | 2021-08-30 |
| CN107872975A (zh) | 2018-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE054165T2 (hu) | Amiszulprid adagolási rendje émelygés és hányás kezelésére | |
| IL258931A (en) | Medicinal compounds and methods | |
| IL259441B1 (en) | Materials and methods for the treatment of titin-based myopathies and other titinopathy | |
| EP3174974A4 (en) | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions | |
| SG11201706767RA (en) | Materials and methods for treatment of hemoglobinopathies | |
| IL266171B (en) | Dosage and therapeutic regimen for hdm2-p53 interaction inhibitors | |
| IL267622A (en) | Method for modifying the therapeutic effects of drugs | |
| PT3189074T (pt) | Composições e métodos para tratar e prevenir a inflamação | |
| IL270011B (en) | Medicinal compounds and methods | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| EP3458098A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A NEUTRAL VECTOR TREATED WITH ENERGY AND METHODS OF TREATMENT THEREOF | |
| GB201521217D0 (en) | Dosage regimens | |
| ZA201802845B (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| IL254003A0 (en) | Improved Hemorrhoid Treatment and Reloading Device | |
| IL266292A (en) | treatment regimens | |
| PT3253406T (pt) | Composições para tratar granulomatose com poliangiite | |
| ZA201803010B (en) | Plasminogen dosage regimen for wound healing | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| GB201504105D0 (en) | Compositions for treatment of nausea and vomiting | |
| GB201517643D0 (en) | Dosage form for melatonin | |
| HK40008165A (en) | Dosage regimen for the treatment of endometriosis | |
| GB201614179D0 (en) | Dosage regimen for the treatment of endometriosis | |
| GB201523012D0 (en) | The combination of chinese medicine for treating infantile cough | |
| GB201409272D0 (en) | Synergistic combination of analgesic drugs |